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Abstract
Background: The relationship between lung dose-volume histogram (DVH) parameters and radiation pneumonitis
(RP) associated with induction concurrent chemoradiotherapy (CCRT) followed by surgery in patients with non-
small cell lung cancer (NSCLC) is unclear, particularly when concerning irradiation of the whole lung prior to
resection. We performed this study to identify factors associated with grade ≥ 2 RP in such patients.
Methods: Patients who received induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 46 Gy/23
fractions) between May 2003 and May 2017 were reviewed. The mean lung dose (MLD) and the percentage of the
lung volume that received ≥5 Gy (V5) and ≥ 20 Gy (V20) were calculated. Factors associated with the development
of grade ≥ 2 RP were analyzed.
Results: One hundred and eight patients were included in this study, 34 (31.5%) of whom experienced grade≥ 2 RP.
A V20≥ 21%, an MLD ≥10 Gy, and a lower lobe tumor location were significant predictors of grade≥ 2 RP on
univariate analysis (p = 0.007, 0.002, and 0.004, respectively). Moreover, an MLD ≥10 Gy and lower lobe location were
significant predictors of grade≥ 2 RP on multivariate analysis (p = 0.026 and 0.0043, respectively). The cumulative
incidence rates of grade≥ 2 RP at 6 months were 15.7 and 45.6% in patients with MLDs < 10 Gy and≥ 10 Gy,
respectively, and were 23.5 and 55.6% in patients with upper/middle lobe- vs. lower lobe-located tumors, respectively.
Conclusions: MLD and lower lobe location were predictors of grade≥ 2 RP in patients who received induction CCRT.
It is necessary to reduce the MLD to the greatest extent possible to prevent the occurrence of this adverse event.
Keywords: Radiation pneumonitis, Mean lung dose, Lower lobe, Induction chemoradiotherapy, Non-small cell lung
cancer
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Background
Definitive concurrent chemoradiotherapy (CCRT) is
considered a standard therapy for patients with locally
advanced stage III non-small-cell lung cancer (NSCLC);
the concurrent administration of docetaxel and cisplatin
has shown promising results [1]. However, long-term
local control rates remain inadequate, leading to various
treatment strategies that may include surgical resection
[2]. Meta-analyses of individual participant data regard-
ing preoperative chemotherapy have shown improved
survival for patients with stage IB–IIIA NSCLC [3].
Moreover, some researchers have attempted to incorpor-
ate radiotherapy into induction therapy. At our institu-
tion, Toyooka et al. demonstrated that the 3- and 5-year
overall survival rates of patients who received induction
CCRT were significantly higher than those of patients
who received induction chemotherapy [4]. The phase III
INT 0139 randomized controlled trial that compared in-
duction CCRT plus subsequent lobectomy to definitive
CCRT without surgery in patients with stage III NSCLC
found that the overall survival was poorer in the latter
group than in the former [5].
Radiation pneumonitis (RP) is a notable adverse event
after thoracic radiotherapy. A recent breakthrough phase
III trial of durvalumab after CCRT showed significantly
longer progression-free survival in patients administered
durvalumab than in those administered a placebo [6].
However, one of the exclusion criteria in that trial was
grade 2 or higher RP resulting from a previous CCRT
regimen.
While previous studies have investigated the correlation
between the dose-volume histogram (DVH) parameters
and RP in patients who received definitive CCRT [7–12],
there are (to our knowledge) only 2 published studies in-
vestigating the relationship between RP and DVH parame-
ters in patients who underwent induction CCRT. One
study by Takahashi et al. that investigated the relationship
between RP and DVH parameters revealed that the irradi-
ation of ≥12% of the remnant (post-resection) lung vol-
ume with at least 20 Gy (V20) and lobectomy were
significant factors of RP on univariate analysis [13]. More-
over, our own previous study was the first to show that
the V20 to the remnant lung was a predictive factor for
RP on multivariate analysis [14]. Analyses of DVH-CCRT
associations usually investigate the V20 and mean lung
dose (MLD), although the preoperative resection target
volume may change after induction CCRT. However, the
aforementioned 2 studies did not show that the V20 and
MLD to the total lung (i.e., pre-resection) were signifi-
cantly associated with grade ≥ 2 RP.
In the present study, we investigated the relationship
between whole-lung DVH parameters and the develop-
ment of grade ≥ 2 RP in patients receiving induction
CCRT for NSCLC.
Methods
Patients
Data from patients with histologically confirmed NSCLC
who received induction CCRT between May 2003 and
May 2017 at our institution were reviewed retrospect-
ively. Induction CCRT mainly administered to patients
with resectable bulky N2–3 tumors, although some pa-
tients also underwent this procedure based on the sur-
geon’s discretion. The eligibility criteria for this study
were as follows: radiotherapy administered at a dose of
46 Gy in 23 fractions, chemotherapy with cisplatin/doce-
taxel administered concurrently with radiotherapy, and
the completion of the preplanned surgery after induction
CCRT. All procedures followed were in accordance with
the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. Written informed
consent was obtained from each patient before treat-
ment. Moreover, through notifications displayed in the
outpatient ward and on the institution’s website, patients
were provided the option to opt-out of this study. The
institutional review board of Okayama University Gradu-
ate School of Medicine, Dentistry and Pharmaceutical
Sciences and Okayama University Hospital approved this
study (approval number: 1809–018).
Treatment
Physical examination, chest radiography, chest and ab-
dominal computed tomography (CT), brain magnetic
resonance imaging, bone scans, and fluorodeoxyglucose
positron emission tomography-CT were performed to
obtain detailed data for staging, which was determined
using the 7th edition of the TNM classification of malig-
nant tumors. Treatment planning for radiotherapy was
performed using 2–10mm-thick CT scans obtained at
2–10 mm intervals while patients were in the supine
position without respiratory arrest and tumor tracking.
The gross tumor volume (GTV) included the primary
tumors and clinically diagnosed metastatic nodal sta-
tions. The clinical target volume included the GTV with
a 5–10 mm margin plus the non-metastatic subcarinal
and ipsilateral hilar nodal stations; prophylactic nodal ir-
radiation to the non-metastatic nodal stations was not
performed after 2015. The planning target volume in-
cluded the clinical target volume with a 5–10mm mar-
gin and consideration for the internal and setup
margins. The internal margin was determined at the dis-
cretion of the attending doctor based on X-ray fluoros-
copy images. All patients underwent 3-dimensional
treatment planning using the Xio computer software
version 4.8.0 (Elekta, Sweden) with a superposition dose
calculation algorithm for heterogeneity correction. The
prescribed dose at the isocenter was 46 Gy, with 2 Gy
per fraction once daily, using a 10 MV photon beam
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delivered by a linear accelerator (Mevatron Primus or
ONCORCanon, Japan).
The chemotherapy regimen was cisplatin/docetaxel in
all patients, and was concurrently administered with
radiotherapy based on the OLCSG 0007 trial [1]. The
preplanned surgery was performed approximately 1
month after the completion of radiotherapy.
Evaluation
The DVH parameters of the total lung minus the gross
tumor were considered. Lung contouring was performed
automatically using the CT-based threshold; the trachea
and bronchi were manually excluded. The RP grade was
determined according to the Common Toxicity Criteria
for Adverse Events (CTCAE) version 4.0. The diagnostic
criteria for radiation pneumonitis were as follows: Grade
1: Asymptomatic; clinical or diagnostic observations
only; intervention not indicated; Grade 2: Symptomatic;
medical intervention indicated; limiting instrumental ac-
tivities of daily living (ADL); Grade 3: Severe symptoms;
limiting self-care ADL; oxygen indicated; Grade 4: Life-
threatening respiratory compromise; urgent intervention
indicated; and Grade 5: Death. The MLD and the per-
centage of the lung volume that received more than 5
Gy (V5) and 20 Gy (V20) were analyzed as DVH param-
eters; the relationships between these parameters and
the incidences of grades ≥2 RP were investigated via uni-
variate analysis with Fisher’s exact test as well as multi-
variate analysis using the Cox proportional hazards
model. Before performing Fisher’s exact test, we used
the median cutoff value to convert continuous parame-
ters to binomial ones.
Statistical significance was defined as p < 0.05; factors
found to be significant on univariate analysis were sub-
jected to multivariate analysis. The cumulative incidence
rate of RP was determined using the Kaplan-Meier
method stratified by factors found to be significant on
multivariate analysis. The R software, version 3.2.0 (R
Foundation for Statistical Computing) was used for all
statistical analyses.
Results
One hundred and eight patients were included in this
study; their characteristics are shown in Table 1. One
stage IV patient had axillary lymph node metastasis that
was surgically removed. All the patients received induc-
tion CCRT with a dose of 46 Gy. Ten patients who did
not undergo surgery after induction CCRT due to rea-
sons, such as appearance of distant metastasis before
surgery in seven patients, deterioration of general condi-
tion in one patient, deterioration of general condition
due to RP in one patient, and refusal of surgery after re-
mission of RP in one patient, were excluded in this
study. The median interval to surgery was 5.8 weeks
(range: 3.1–13.0 weeks) after completion of radiotherapy.
Lobectomy, bilobectomy, and pneumonectomy were
performed in 86, 14, and 8 patients, respectively. The
median follow-up period after completion of radiother-
apy was 42.9 months (range: 2.0–152.1). The median
V20 and MLD were 20.7% (range: 7.0–38.5%) and 10.3
Gy (range: 3.5–14.5 Gy), respectively.
A total of 30, 43, 32, and 3 patients experienced RP
with grades 0, 1, 2 and 3, respectively. The median
period from completion of induction CCRT to the onset
of grade ≥ 2 RP was 7.6 weeks (range: 4.3–56 weeks). Of
the 35 patients with grade ≥ 2 RP, 6 experienced this
toxicity before surgery. All 6 patients developed G2 RP.
The mean values of V5, V20, and MLD were 31.6,
21.3%, and 10.5 Gy in the group that developed ≥2 RP
before surgery and 37.7, 24.8%, and 12.1 Gy in the group
that developed ≥2 RP after surgery, respectively. There
was no significant difference between the two groups
(p = 0.269, 0.386, and 0.404, respectively). Figure 1 shows
the cumulative incidence rate of grade ≥ 2 RP (32.4, 95%
confidence interval: 23.7–42.1) at 6 months.
The results of univariate and multivariate analyses of fac-
tors associated with grade ≥ 2 RP are shown in Table 2. A
V20 ≥ 21%, an MLD ≥10Gy, and a tumor location in the
lower lobe were found to be statistically significant factors
on univariate analyses (p = 0.007, 0.002, and 0.004, respect-
ively). There was a tendency for RP to occur more easily in
the group with reduced residual lung volume than in the
group with normal residual lung volume (p = 0.064). Patient
age, sex, performance status, smoking status, resection
range, forced expiratory volume in 1 s, and V5 were not sig-
nificantly associated with the development of grade ≥ 2 RP.
On multivariate analysis, the MLD and tumor location were
found to be significantly associated with grade ≥ 2 RP (p =
0.026 and 0.004, respectively). According to the cut-off
value established by Tsujino et al. [8], the cumulative inci-
dence rates at 6months were 23.7 and 50.0% in patients
with V20 s ≤25 and > 25%, respectively.
Figure 2 shows the cumulative incidence rates of
grades ≥2 RP stratified according to MLD and tumor lo-
cation. The rates of grade ≥ 2 RP at 6 months were 15.7
and 45.6% in patients with MLDs < 10 Gy and ≥ 10 Gy,
respectively, and were 23.5 and 55.6% in patients with
upper/middle lobe location and lower lobe location, re-
spectively. In groups with ≥2 RP and < 2 RP, the five-
year disease-free survival rates were 55.1 and 62.9%, re-
spectively, and the five-year overall survival rates were
81.3 and 73.5%, respectively. There were no significant
differences between the two groups (p = 0.6 and 0.5,
respectively).
Discussion
RP often occurs in patients undergoing definitive radio-
therapy for NSCLC, although grade 5 RP is rare [8, 9,
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12]. Among the DVH parameters, V20 and MLD are the
most common predictors of RP in patients undergoing
definitive radiotherapy with or without chemotherapy.
Graham et al. reported that V20 was the sole independ-
ent predictor of RP [7], as none of their patients devel-
oped this adverse effect when V20 was less than 22, 8%
developed RP grade ≥ 2 RP when V20 was 22–31, and
13% did when V20 was 32–40%. One-half of their pa-
tients were treated with radiotherapy alone. While the
incidence rate of RP has risen in the era of CCRT, Tsu-
jino et al. found that the V20 was the sole factor associ-
ated with grade ≥ 2 RP after definitive CCRT [8]; the 6-
month cumulative incidences of grade ≥ 2 RP were 8.7,
18.3, 51, and 85% in patients with V20 s of < 20%, 21–
25%, 26–30, and > 31%, respectively. The 6-month cu-
mulative incidence of grade ≥ 2 RP among their patients
was 14% in those with V20 s up to 25 and 63% in those
Table 1 Patient characteristics
%
Age (years)
Median (range) 62 (34–79) –
Sex
Male 80 74
Female 28 26
ECOG-PS
0 64 59
1 42 39
2 1 1
Smoking History (Brinkmann Index)a
Median (range) 760 (0–3120) –
Lobe
Upper 72 67
Middle 9 8
Lower 27 25
Laterality
Right 62 57
Left 46 43
Histology
Adenocarcinoma 50 46
Squamous cell carcinoma 42 39
Undifferentiated carcinoma 1 1
Non-small cell carcinoma 15 14
C-stage
IIA 4 4
IIB 9 8
IIIA 66 61
IIIB 28 26
IV 1 1
Operation
Lobectomy 86 80
Bilobectomy 14 13
Pneumonectomy 8 7
FEV1 (l)a
Median (range) 2.52 (1.40–4.06) –
Tumor size (mm)
Median (range) 44.33 (15.64–107.00) –
GTV volume (cc)
Median (range) 66.25 (10.17–601.44) –
Number of lymph nodes
Median (range) 2 (0–11) –
Resected lung volume (cc)
Median (range) 734.54 (52.82–1759.25) –
Residual lung volume (cc)
Table 1 Patient characteristics (Continued)
%
Median (range) 2503.98 (953.54–4415.03) –
V5 (%)
Median (range) 32.0 (10.8–54.9) –
V20 (%)
Median (range) 20.7 (7.0–38.5) –
MLD (Gy)
Median (range) 10.3 (3.5–17.7) –
Period from completion of RT to surgery (weeks)
Median (range) 5.9 (3.1–13.0) –
ECOG-PS Eastern Cooperative Oncology Group performance status, FEV1
Forced expiratory volume in 1 s, GTV Gross tumor volume, RT Radiotherapy.
aThese factors have missing values
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Fig. 1 Cumulative incidence rate of grade≥ 2 radiation pneumonitis
after completion of radiotherapy. The broken lines indicate 95%
confidence intervals
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with V20 s ≥26%. Data from a large meta-analysis of pre-
dictors of RP showed that the rates of symptomatic RP
were 18.6 and 30.3% in patients with V20 s < 20% and
20–29.99%, respectively, and the rates of fatal pneumon-
itis were 2.9 and 3.5% in patients with V20 s of 30–40%
and ≥ 40%, respectively [9]. In our study, the cumulative
rates of grade ≥ 2 RP at 6 months were 23.7 and 50.0% in
patients with V20 s of ≤25 and > 25%, respectively, ac-
cording to the cut-off value established by Tsujino et al.
[8]. While comparing the incidences of RP between pre-
vious studies and ours should be performed with cau-
tion, owing to the reliance on different CTCAE versions
and V20 cut-off values, the grade ≥ 2 RP rates in our
study appeared to be within range of those previously re-
ported in patients who received definitive CCRT. On the
other hand, none of our patients experienced fatal PR. In
our study, however, we targeted patients who were likely
to tolerate surgery before starting induction CCRT;
Table 2 Univariate and multivariate analyses of factors associated with grade ≥ 2 radiation pneumonitis
Factor N Univariate
p-value
Odds ratio
(95% CI)
Multivariate
p-value
Age (years) < 62 18/51 0.681 – NE
≥62 17/57
Sex Male 24/80 0.482 – NE
Female 11/28
ECOG-PS a 0 24/64 0.215 – NE
1–2 11/43
Smoking history (Brinkmann Index)a < 760 17/49 0.673 – NE
≥760 16/55
Lobe Lower lobe 15/27 0.004 3.75 0.004
Upper/Middle lobe 20/81 (1.39–10.5)
Laterality Right 21/62 0.836 –
Left 14/46
Surgery Lobectomy 26/86 0.350 – NE
Bilobectomy 7/14
Pneumonectomy 2/8
FEV1 (L)a < 2.5 13/48 0.293 – NE
≥2.5 20/53
Tumor size (mm) < 44 22/54 0.099 – NE
≥44 13/54
GTV volume (cc) < 66 20/53 0.305 – NE
≥66 15/55
Number of lymph < 2 10/44 0.095 – NE
Nodes ≥2 25/64
Resected lung < 730 16/53 0.684 – NE
volume (cc) ≥730 19/55
Residual lung < 2500 22/53 0.064 – NE
volume (cc) ≥2500 13/55
V5 (%) < 32 13/55 0.064 – NE
≥32 22/53
V20 (%) < 21 11/55 0.007 3.27 0.349
≥21 24/53 (1.31–8.62)
MLD (Gy) < 10 9/51 0.002 3.86 0.026
≥10 26/57 (1.50–10.8)
CI Confidence interval, NE Not entered, ECOG-PS Eastern Cooperative Oncology Group Performance Status, FEV1 Forced expiratory volume in 1 s, GTV Gross tumor
volume, MLD Mean lung dose of the lung, V20 Percentage of the lung volume receiving at least 20 Gy.
aThese variables have missing values
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because definitive CCRT is usually indicated for unre-
sectable locally advanced NSCLC, our patients may have
been in relatively better condition than those investi-
gated in previous studies.
MLD is also an important predictor of RP in patients
undergoing definitive CCRT. Barriger et al. reported that
the rates of grade ≥ 2 RP were 2.2 and 19% in patients
with MLDs < 18 Gy and > 18 Gy, respectively [12]. Palma
et al. also found the MLD to be a predictor of RP in the
patients ≤65 years treated with carboplatin/paclitaxel
chemotherapy using recursive partitioning analysis [9];
the rates of RP were 0–9% and 41–48% among patients
with MLDs < 10 Gy and ≥ 10 Gy, respectively. In our
study, the RP rates at 6 months were 15.7 and 45.6% in
patients with MLDs < 10 Gy and ≥ 10 Gy, respectively,
which are consistent with Palma et al.’s data. Dang et al.
found that the MLD is a predictor of grade ≥ 2 RP using
multivariate logistic regression analysis, with an odds ra-
tio of 1.42 (95% confidence interval: 1.28–1.58) [11].
Hence, the fact that MLD and V20 were predictors of
RP in our study is consistent with other published data
of patients who underwent definitive CCRT.
Takahashi et al. investigated the relationship between
RP and DVH parameters among patients with NSCLC
treated with induction CCRT and surgery, and found
that a V20 to the resected lung (i.e., post-lobectomy) of
≥12% was a significant predictor of grade ≥ 2 RP [13].
However, neither the MLD nor V20 to the whole lung
was significantly associated with grade ≥ 2 RP in their
study, even on univariate analysis. However, V20 and
MLD to the whole lung were statistically significant
factors in our univariate analyses, whereas MLD was also
significant on multivariate analysis. To our knowledge,
our study is the first to show that MLD and V20 to the
whole lung are predictors of grade ≥ 2 RP in patients
undergoing induction CCRT.
Previous investigators have reported that a lower lobe
tumor location is predictive of grade ≥ 2 RP development
in patients receiving definitive chemoradiotherapy (CRT)
[9–11]. For example, Park et al. found that, among pa-
tients treated with 3-dimensional conformal radiother-
apy as part of definitive CRT for NSCLC, 40% of those
with lower lobe tumor locations developed grade ≥ 2 RP
compared to 25% of those with upper and middle lobe
locations; the difference was significant on univariate
analysis [10]. Dang et al. also revealed that a lower lobe
tumor location was significantly associated with grade ≥
2 RP on univariate analysis [11]. Their group investi-
gated 369 consecutive patients with stage III NSCLC
who were treated with CRT, and found that the inci-
dences of RP in 235/134 patients with upper/lower lobe
tumor locations were 164/76 for grades 0–1, 48/32 for
grade 2, and 23/26 for grade 3. The rates of grade ≥ 2 RP
in patients with upper and lower lobe tumor locations
were 30.2 and 43.3%, respectively. While our data are
comparable to those of previous studies, the rates of
grade ≤ 2 RP were 23.5 and 55.6% in patients with
upper/middle lobe and lower lobe tumor locations, re-
spectively; hence, the difference in grade ≥ 2 RP inci-
dence between patients with upper and lower lobe
tumor locations was greater than that in previous stud-
ies. We also found that tumor location was a significant
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Fig. 2 Subgroup analysis of the incidence of grade≥ 2 radiation pneumonitis after completion of radiotherapy. a Cumulative incidence rate
grade≥ 2 radiation pneumonitis stratified according to the mean lung dose (MLD). b Cumulative incidence rate of grade≥ 2 radiation
pneumonitis stratified according to the tumor location in the lung
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predictor of grade ≥ 2 RP on multivariate analysis. In
Palma et al.’s study, fatal RP (which occurred in 1.9% of
patients) was found to be associated with tumor loca-
tion, with 1, 0, and 5% of RP-related fatalities occurring
in patients with tumors in the upper, middle, and lower
lobes, respectively (p = 0.007) [9]. Further studies are re-
quired to understand why a lower lobe tumor location is
an independent predictor of RP in patients undergoing
induction CCRT. There was a tendency for ≥2 RP to
occur more easily in the group with reduced residual
lung volume than in the group with normal residual
lung volume. This result is consistent because a patient
with small lung volume is likely to develop symptoms of
respiratory disease. In the study by Takahashi et al.,
there was no significant difference in the residual lung
volume [11]. However, the small sample size was one of
the limitations of that study, and the difference in results
between our study and that of Takahashi et al. may be
due to the difference in sample size.
Various methods have been tried to improve radio-
therapy dose distribution. Intensity-modulated radiation
therapy (IMRT) is advantageous over 3-dimensional
conformal radiotherapy in terms of avoiding adjacent
organs-at-risk. A prospective phase I study found that
IMRT was associated with a global decrease in normal
tissue exposure compared to 3-dimensional conformal
radiotherapy, and that the former as associated with a
significant reduction in V20 (21.5% vs. 26.5%, p <
0.01) and MLD (11.9 Gy vs. 14.9 Gy, p < 0.01) com-
pared to the latter [15]. Chun et al. performed a sec-
ondary analysis of the RTOG 0617 trial and found
that patients in the IMRT group had significantly
lower occurrences of grade ≥ 3 RP than did those in
the 3-dimensional conformal radiotherapy group
(7.9% vs. 3.5%, p = 0.039) [16].
In the near future, it might also be possible to use pro-
ton beam therapy to deliver a sufficient radiation dose
without increasing lung toxicity. Berman et al. compared
dose distributions between IMRT and intensity modu-
lated proton therapy in 10 patients with pathologic stage
IIIA NSCLC [17]. The CT treatment planning scans for
IMRT (50.4 Gy in 1.8 Gy fractions to the target volume)
were used, and the average MLDs, when using IMRT
and proton therapy, were 10.83 Gy and 6.675 Gy, re-
spectively. Hence, they were able to reduce the MLD
to below 10 Gy, which was the cut-off value in our
study by using IMPT. Such newer technologies may
enable MLD reductions to the lowest doses possible;
however, it remains necessary to perform prospective
studies to compare the effectiveness and lung toxicity
profiles of IMRT and intensity modulated proton
therapy for induction CCRT.
To the best of our knowledge, our study is the first to
show that MLD and tumor location are significant
predictors of RP in patients undergoing induction CCRT
for NSCLC. However, our study had certain limitations.
First, it was a retrospective analysis in which certain pa-
tient details were unknown; for example, Kocak et al. re-
ported that RP scoring was difficult in 28% of their
patients because of confounding medical conditions [18].
Second, although induction CCRT was administered to
patients judged to be operable by the surgeon, detailed
assessments on the underlying lung disease using CT
were not made. For example, Tujino et al. found that the
pulmonary fibrosis score as determined via baseline CT
was a better predictor of grade ≥ 2 RP than V20 alone
according to receiver operating characteristic analysis
[19]. Third, limited information was available regarding
internal target volume, surgical invasiveness, and surgical
morbidity due to the retrospective nature of the study.
Conclusions
MLD and lower lobe location were predictors of grade ≥
2 RP in patients with NSCLC who received induction
CCRT. Therefore, it is necessary to reduce MLD during
radiotherapy planning to the greatest extent possible to
prevent the occurrence of this adverse event.
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